DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Residual Disease Kinetics in High-Risk CLL Patients: Ibr+Ven vs Clb+O Mar 23, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Real-World Comparison of ACP-196 and Ibrutinib in CLL Treatment Mar 23, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Safety and Tolerability of Pirtobrutinib in B-Cell Malignancies: BRUIN Phase 1/2 Study Mar 07, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma A Promising Phase 1/2 Study of Pirtobrutinib in R/R CLL/SLL Patients Pre-Treated with cBTKi Mar 07, 2023
FL (Follicular Lymphoma),Lymphoma,Popular Comparing HRQOL in R/R Large B-cell Lymphoma: Liso-cel vs SOC Feb 24, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Polatuzumab Vedotin in First-Line DLBCL Treatment: Phase 3 POLARIX Trial Analysis in Asian Subpopulation Feb 24, 2023
FL (Follicular Lymphoma),Lymphoma Subcutaneous Epcoritamab Phase II Trial in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion Study Feb 16, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Ibrutinib Plus R-CHOP for BCL2 and MYC Co-Expressing DLBCL: Phase 3 Results from the PHOENIX Trial Feb 16, 2023
